Evidence map›Paper›PMID 41766047›Full record

ArticleScientific reports2026

The effect of medication use on chronic pruritus in patients with type 2 diabetes mellitus: a multicenter cross-sectional study.

Min Xu, Ximan Gao, Zirong Liu, Li Zhang, Zhanglong Wang, Huiru Zhuang, Wenlong Fu, Siyu Yao, Lin Zhang, Saijun Zhou and 1 more

Abstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Min XuNHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, 300134, People's Republic of China.ORCID http://orcid.org/0009-0006-7123-8800
Ximan Gao *NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, 300134, People's Republic of China.ORCID http://orcid.org/0009-0007-0827-2237
Zirong Liu *Department of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin, 300192, People's Republic of China.ORCID http://orcid.org/0000-0002-1731-0035
Li ZhangNHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, 300134, People's Republic of China.
Zhanglong WangNHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, 300134, People's Republic of China.
Huiru ZhuangNHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, 300134, People's Republic of China.
Wenlong FuNHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, 300134, People's Republic of China.
Siyu YaoNHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, 300134, People's Republic of China.
Lin ZhangNHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, 300134, People's Republic of China.
Saijun ZhouNHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, 300134, People's Republic of China. zhousaijun@tmu.edu.cn.ORCID http://orcid.org/0000-0002-5761-7568
Juping LiuTianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute, School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, People's Republic of China. tydljp@126.com.ORCID http://orcid.org/0000-0002-5312-7748

Funding

Bethune Charitable Foundation Z04JKM2022E035Key Project of Science and Technology Fund of Tianjin Municipal Health Commission TJWJ2025ZD004National Natural Science Foundation of China 82570950Science and Technology Fund of Tianjin Municipal Education Commission 2024ZD036, 2023KJ103the China Endocrine Metabolism Talent Research Fund 2023-N-03-15the Tianjin Key Medical Discipline (Specialty) Construction Project TJYXZDXK-032ATianjin Key Medical Discipline Construction Project TJYXZDXK-3-007B
6 · The paper itself

Abstract

This study aimed to investigate the association between various types of medications and chronic pruritus (CP) in patients with type 2 diabetes mellitus (T2DM) through a large cross-sectional study. This study encompassed data from the Tianjin Community-Based Diabetic Retinopathy Screening Cohort, comprising 2,059 patients with T2DM who were enrolled from eight community centers. The exposure variables were different medication classes, and the outcome variable was CP symptoms. The prevalence of CP in patients with T2DM was 41.3% (851/2059). After adjusting for potential confounding factors, α-glucosidase inhibitor (AGIs) (adjusted OR 1.272, 95%CI 1.050–1.541), DPP-4 inhibitors (DPP-4is) (adjusted OR 1.286, 95%CI 1.006–1.642), and statins(adjusted OR 1.411, 95%CI 1.151–1.729) remained independently associated with higher odds of CP. In addition, the odds of CP increased progressively with the number of medications used (from one to three drugs; ORs ranging from 1.230 to 1.961). Subgroup analyses further identified a significant interaction between AGI use and renal impairment, with higher odds of CP observed among patients with renal impairment. (P for interaction < 0.05). CP in patients with T2DM was associated with the use of AGIs, DPP-4is, and statins. Moreover, a significant interaction was observed between renal impairment and the use of AGIs.

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsPruritusAgedChronic DiseaseCross-Sectional StudiesDipeptidyl-Peptidase IV InhibitorsFemaleGlycoside Hydrolase InhibitorsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPrevalenceDipeptidyl-Peptidase IV InhibitorsGlycoside Hydrolase InhibitorsHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsAntidiabetic agentsChronic pruritusMulticenter studyStatinsType 2 diabetes mellitus

Identifiers

PMID41766047
PMCPMC13056952

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.